title: A case with acute quadriplegic myopathy following intensive care for idiopathic interstitial pneumonia.
abstract: We reported a patient who developed acute quadriplegic myopathy (AQM) following treatment with a combination of high-dose steroid and nondepolarizing blocking agent for idiopathic interstitial pneumonia (IIP). Few cases of AQM with IIP have been reported in the literature. The HP progressed rapidly in our patient, but the high-dose steroid therapy was effective. The rehabilitative intervention comprised of passive range-of-motion exercise, functional training, and muscle strengthening. After the initial presentation with severe weakness, the AQM gradually improved and the patient regained full physical function in 8 months. The clinical course was almost identical to that of AQM patients with other lung diseases. Though unlikely to influence the improvement of muscle weakness in AQM patients, the lung diseases associated with AQM may require specific consideration in determining suitable rehabilitation programs and observing patients before and after full recovery from dysmobility.
authors.affiliation: Department of Rehabilitation Medicine, Tokai University Oiso Hospital, Nakagun, Kanagawa, Japan. toyokura@juno.dti.ne.jp
authors.forename: Minoru
authors.initials: M
authors.lastname: Toyokura
authors.forename: Chieko
authors.initials: C
authors.lastname: Fujii
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Urano
authors.forename: Kenzo
authors.initials: K
authors.lastname: Nishiya
authors.forename: Akira
authors.initials: A
authors.lastname: Ishida
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D003422:Critical Care; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008775:Methylprednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D011782:Quadriplegia / Q000139:chemically induced* / Q000503:physiopathology; D014673:Vecuronium Bromide / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D008775:Methylprednisolone